New hope for tough lymphoma: TR115 faces off against standard care
NCT ID NCT07639879
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called TR115 in about 180 adults with a rare blood cancer (T/NK-cell lymphoma) that has come back or not responded to prior treatments. Participants will receive either TR115 or one of several standard drugs. The main goal is to see if TR115 can slow cancer growth longer. This is a Phase 3 trial, meaning it is in late-stage testing to compare effectiveness and safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NK/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Cancer Hospital
Beijin, Beijing Municipality, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug spare healthy cells while killing lymphoma?
- Can a targeted pill boost Chemo's power against a rare blood cancer?
- New study aims to decode PTCL by genetic subtype
- New CAR-T therapy targets tough T-Cell cancers in early trial
- New blood test could help monitor T-Cell lymphoma
- New vaccine aims to fight Hard-to-Treat EBV cancers